- Home
- LIQT vs NRXP Comparison
LIQT vs NRXP Comparison
Compare LIQT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIQT
- NRXP
- Stock Information
- Founded
- LIQT 2004
- NRXP 2015
- Country
- LIQT Denmark
- NRXP United States
- Employees
- LIQT N/A
- NRXP N/A
- Industry
- LIQT Industrial Machinery/Components
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- LIQT Technology
- NRXP Health Care
- Exchange
- LIQT Nasdaq
- NRXP Nasdaq
- Market Cap
- LIQT 14.0M
- NRXP 14.8M
- IPO Year
- LIQT N/A
- NRXP N/A
- Fundamental
- Price
- LIQT $1.53
- NRXP $1.19
- Analyst Decision
- LIQT Strong Buy
- NRXP Strong Buy
- Analyst Count
- LIQT 2
- NRXP 3
- Target Price
- LIQT $5.58
- NRXP $31.33
- AVG Volume (30 Days)
- LIQT 14.5K
- NRXP 158.2K
- Earning Date
- LIQT 11-14-2024
- NRXP 11-14-2024
- Dividend Yield
- LIQT N/A
- NRXP N/A
- EPS Growth
- LIQT N/A
- NRXP N/A
- EPS
- LIQT N/A
- NRXP N/A
- Revenue
- LIQT $15,128,295.00
- NRXP N/A
- Revenue This Year
- LIQT $5.96
- NRXP N/A
- Revenue Next Year
- LIQT $32.89
- NRXP N/A
- P/E Ratio
- LIQT N/A
- NRXP N/A
- Revenue Growth
- LIQT N/A
- NRXP N/A
- 52 Week Low
- LIQT $1.52
- NRXP $1.10
- 52 Week High
- LIQT $3.75
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- LIQT 33.32
- NRXP 37.26
- Support Level
- LIQT $1.82
- NRXP $1.12
- Resistance Level
- LIQT $1.99
- NRXP $1.30
- Average True Range (ATR)
- LIQT 0.14
- NRXP 0.10
- MACD
- LIQT 0.00
- NRXP 0.00
- Stochastic Oscillator
- LIQT 2.72
- NRXP 21.21
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.